SYNKLINO

Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation.

SYNKLINO

Social Links:

Industry:

Biotechnology Health Care

Founded:

2017-01-01

Address:

Lyngby, Hovedstaden, Denmark

Country:

Denmark

Website Url:

http://www.synklino.com

Total Employee:

Status:

Active

Contact:

+45 20 12 16 56

Email Addresses:

[email protected]

Total Funding:

31.99 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Office 365 Mail

Similar Organizations

acthera-therapeutics-logo

Acthera Therapeutics

Acthera Therapeutics is developing an innovative nanotechnology-based platform for the controlled and targeted drug delivery

chimeron-bio-logo

Chimeron Bio

Chimeron Bio develops agents for personalized cancer gene therapy.

Current Advisors List

john-haurum_image

John Haurum Chairman Of The Board @ Synklino
Board_member
2019-01-01

Current Employees Featured

thomas-kledal_image

Thomas Kledal
Thomas Kledal CEO and Co-Founder @ Synklino
CEO and Co-Founder
2017-07-01

Investors List

eir-ventures_image

Official Site Inspections

http://www.synklino.com Semrush global rank: 5.9 M Semrush visits lastest month: 1.4 K

Host Informations
Whois Informations

Loading ...